Earnings
RUBY
18.60
-3.63%
-0.70
Currencies: USD
Items
Net Income
Depreciation and Amortization
Deferred Tax
Unamortized Expenditures
Accrued Expenses
Share-based Compensation
Assets Disposal
Financial Expenses
Investment Loss
Working Capital Change
Other Items
Operating Activities
Purchases of Fixed Assets
Proceeds from Disposal of Fixed Assets
Investment Expenditure
Investment Income
Other Investing Activities
Investing Activities
Issuance of Capital Stock
Issuance of Bonds
Proceeds from Borrowings
Dividend Payments
Repayment of Borrowings
Buyback Payments
Stock Incentive Compensation
Other Financing Activities
Financing Activities
Effect of Exchange Rate Changes 
Net Increase in Cash,Cash Equivalents
FY 2020-12-31
-167.73M
5.69M
--
--
--
--
34.28M
--
--
112.00K
--
-127.65M
-5.50M
--
--
--
105.93M
100.43M
1.48M
25.00M
--
--
--
--
--
--
26.48M
--
-732.00K
FY 2019-12-31
-163.46M
3.00M
--
--
--
--
39.58M
--
--
10.44M
--
-110.44M
-40.66M
--
--
--
-91.98M
-132.63M
2.29M
25.00M
--
--
--
--
--
--
27.29M
--
-215.79M
FY 2018-12-31
-89.19M
1.26M
--
--
--
--
29.47M
--
--
119.00K
--
-58.34M
-14.95M
--
--
--
-96.69M
-111.64M
358.92M
19.75M
--
--
--
--
--
--
374.83M
--
204.85M
FY 2017-12-31
-43.85M
447.00K
--
--
--
--
18.73M
--
--
2.73M
--
-21.94M
-2.25M
--
--
--
0.00
-2.25M
120.20M
1.50M
--
--
--
--
--
--
121.69M
--
97.50M
FY 2016-12-31
-11.02M
118.00K
--
--
--
--
257.00K
--
--
1.14M
--
-9.50M
-443.00K
--
--
--
0.00
-443.00K
11.44M
4.00M
--
--
--
--
--
--
15.42M
--
5.47M

FY: Financial Year. It represents annual report.

Q: Quarter Report. Q1、Q2、Q3、Q4 represent three-month periodic financial reports.

Check out RUBY latest annual and quarterly financial reports. There are also historical financial reports for you to reference. You can analyze Rubius Therapeutics recent business situations by check its cash flow statements, balance sheets, income statements and other tables. Comprehensive data may help you to understand and analyze RUBY development prospects in various aspects, and this information may help you to better grasp the Rubius Therapeutics operation.